Printer Friendly

THE LIPOSOME COMPANY GAINS PATENT FOR LIPOSOMAL PROSTAGLANDIN; TLC C-53 BEING DEVELOPED FOR ARDS, SEPSIS/TRAUMA SYNDROME, AMI AND ANGIOPLASTY

THE LIPOSOME COMPANY GAINS PATENT FOR LIPOSOMAL PROSTAGLANDIN; TLC C-53

BEING DEVELOPED FOR ARDS, SEPSIS/TRAUMA SYNDROME, AMI AND ANGIOPLASTY
 PRINCETON, N.J., Jan. 21 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ: LIPO) was today granted a patent covering its TLC C-53, a liposomal prostaglandin E1 (PGE1) (note: the numeral 1 is a subscript), which it is developing as a cell adhesion antagonist. The drug is expected to enter clinical trials by mid-year.
 It will be tested as a treatment for a number of conditions, including Adult Respiratory Distress Syndrome, Sepsis/Trauma Syndrome and Acute Myocardial Infarction (AMI); and as a means to prevent restenosis following Angioplasty.
 TLC C-53 consists of PGE1 encapsulated in liposomes. PGE1 has been shown to be a powerful agent in preventing or reversing the activation and adhesion of certain types of cells, including neutrophils, platelets, and endothelial cells. Because activation and adhesion of these cells are believed to be central to many inflammatory and vasoocclusive diseases, scientists have postulated that PGE1 should be useful in treating or preventing them. However, efforts to capitalize on the therapeutic potential of PGE1 have been stymied, because it is unstable, causes a variety of toxicities at therapeutic doses, and is cleared from the blood rapidly.
 U.S. Patent No. 5,082,664, issued today, protects a broad category of liposome encapsulated prostaglandins and additionally covers novel techniques by which scientists at The Liposome Company have been able to prepare a PGE1 liposome that overcomes the many problems associated with commercial development of a pharmaceutically acceptable form of the drug. The company's liposomal PGE1, TLC C-53, is specifically covered.
 In experiments conducted to date in animal models of ARDS, TLC C-53 has been shown to be much more effective than conventional PGE1. In addition, in animal models of AMI at therapeutic doses, TLC C-53 did not appear to cause the adverse events normally associated with PGE1, such as drops in blood pressure. Scientists have hypothesized that due to its liposomal structure, TLC C-53 is targeted directly to the sites of disease. This seems to result in greater efficacy and safety.
 The Liposome Company is currently completing preclinical testing of TLC C-53 and expects to start clinical trials with the drug later this year.
 The largest company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment and diagnosis of life-threatening illnesses.
 -0- 1/21/92
 /CONTACT: Anne Van Lent, senior vice president and chief financial officer of The Liposome Company, 609-452-7060/
 (LIPO) CO: Liposome Company, Inc. ST: New Jersey IN: MTC SU:


CK-FC -- NY003 -- 1644 01/21/92 09:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 21, 1992
Words:441
Previous Article:PNC TO ACQUIRE FLAGSHIP FINANCIAL FOR $45 MILLION
Next Article:INTEGRA ANNOUNCES 1991 EARNINGS
Topics:


Related Articles
LIPOSOME ACQUIRES CLOT-BUSTER TECHNOLOGY FOR HEART ATTACKS; PATENT TO COVER LIPOSOME-ENCAPSULATED FIBRINOLYTIC AGENTS FOR ARTERY REOPENING
LIPOSOME COMPANY COMPLETES STOCK OFFERING OF 3 MILLION SHARES
THE LIPOSOME COMPANY SELLS ADDITIONAL 450,000 SHARES AS PART OF STOCK OFFERING
LIPOSOME COMPANY'S FOURTH DRUG ENTERS CLINICAL TRIALS; BEING DEVELOPED TO TREAT OFT-FATAL LUNG DISEASE
THE LIPOSOME COMPANY ACQUIRES FOREIGN RIGHTS FOR LIPOSOMAL PGE(1)
THE LIPOSOME COMPANY FILES FOR APPROVAL OF ABLC IN EUROPE
INVESTIGATORS TO PRESENT CLINICAL EFFICACY AND SAFETY DATA FOR ABLC AT ICAAC CONFERENCE; SAFETY DATA STATISTICALLY SIGNIFICANT
THE LIPOSOME COMPANY, INC. REPORTS CLINICAL PROGRESS ON THREE LEAD DRUGS AT HAMBRECHT & QUIST CONFERENCE
LIPOSOME COMPANY DRUG EFFECTIVE IN ARDS PHASE II STUDY; POSITIVE RESULTS WITH TLC C-53 REPORTED AT SOCIETY OF CRITICAL CARE MEDICINE
THE LIPOSOME COMPANY TO COMMENCE PHASE III CLINICAL STUDY OF TLC C-53 IN ARDS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters